Literature DB >> 12799331

Preoperative predictors of malignancy in pancreatic intraductal papillary mucinous neoplasms.

Chad A Wiesenauer1, C Max Schmidt, Oscar W Cummings, Constantin T Yiannoutsos, Thomas J Howard, Eric A Wiebke, Robert J Goulet, Lee McHenry, Stuart Sherman, Glen A Lehman, Harvey Cramer, James A Madura.   

Abstract

HYPOTHESIS: Malignant intraductal papillary mucinous neoplasms (IPMNs) can be predicted before surgery.
DESIGN: Retrospective review of a prospectively collected database.
SETTING: Academic, urban, tertiary care hospital. PATIENTS: Sixty-four consecutive patients with a pathological diagnosis of IPMN.
INTERVENTIONS: All 64 patients underwent surgical intervention for IPMN between December 8, 1988, and October 16, 2002. MAIN OUTCOME MEASURES: Reliable predictors of malignancy.
RESULTS: The 64 patients underwent 69 operations: 39 pancreaticoduodenectomies, 18 distal pancreatectomies, 7 total pancreatectomies, 4 neck and/or body pancreatectomies, and 1 cystgastrostomy with pancreatic biopsy. Twenty-three of 69 specimens were malignant-12 in situ (high-grade dysplasia) and 11 invasive. In a univariate analysis of 12 clinical signs or symptoms recorded, diabetes mellitus and jaundice showed a significant association with malignancy of IPMN. Of 24 serum chemistry studies, hematologic studies, and tumor marker analyses (in serum, bile, and pancreatic fluid), elevation of serum alkaline phosphatase and glucose levels showed correlation with malignancy. Computed tomography, ultrasound, and endoscopic retrograde cholangiopancreatography findings did not distinguish between benign and malignant tumors. Atypia on preoperative cytologic analysis was specific for malignancy (93%) but lacked the same degree of sensitivity (40% in situ, 91% invasive, and 67% overall).
CONCLUSIONS: Malignancy of IPMNs is suggested by new-onset diabetes mellitus, jaundice, and elevations in serum glucose or alkaline phosphatase levels. Atypia on preoperative cytologic testing is the finding most predictive of malignancy. The absence of these features does not predict benign disease. These findings may help guide patient and physician decision making.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12799331     DOI: 10.1001/archsurg.138.6.610

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  27 in total

1.  Predictive factors associated with malignancy of intraductal papillary mucinous pancreatic neoplasms.

Authors:  Jin Hee Lee; Kyu Taek Lee; Jongwook Park; Sun Youn Bae; Kwang Hyuck Lee; Jong Kyun Lee; Kee-Taek Jang; Jin Seok Heo; Seong Ho Choi; Dong Wook Choi; Jong Chul Rhee
Journal:  World J Gastroenterol       Date:  2010-11-14       Impact factor: 5.742

2.  CT vs MRCP: optimal classification of IPMN type and extent.

Authors:  Joshua A Waters; C Max Schmidt; Jason W Pinchot; Patrick B White; Oscar W Cummings; Henry A Pitt; Kumar Sandrasegaran; Fatih Akisik; Thomas J Howard; Attila Nakeeb; Nicholas J Zyromski; Keith D Lillemoe
Journal:  J Gastrointest Surg       Date:  2007-10-05       Impact factor: 3.452

3.  Decision making for pancreatic resection in patients with intraductal papillary mucinous neoplasms.

Authors:  Bin Xu; Wei-Xing Ding; Da-Yong Jin; Dan-Song Wang; Wen-Hui Lou
Journal:  World J Gastroenterol       Date:  2013-03-07       Impact factor: 5.742

4.  Predictive value of serum carbohydrate antigen 19-9 in malignant intraductal papillary mucinous neoplasms.

Authors:  Bin Xu; Wen-Yan Zheng; Da-Yong Jin; Wei-xing Ding; Wen-Hui Lou; Lajeswar Ramsohok
Journal:  World J Surg       Date:  2011-05       Impact factor: 3.352

5.  The clinicopathologic features of intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Xinyu Qin; Fenglin Liu
Journal:  Front Med China       Date:  2007-02-01

Review 6.  Diagnosis and management of relapsing pancreatitis associated with cystic neoplasms of the pancreas.

Authors:  William-R Brugge
Journal:  World J Gastroenterol       Date:  2008-02-21       Impact factor: 5.742

7.  Plectin-1 is a biomarker of malignant pancreatic intraductal papillary mucinous neoplasms.

Authors:  Dirk Bausch; Mari Mino-Kenudson; Carlos Fernández-Del Castillo; Andrew L Warshaw; Kimberly A Kelly; Sarah P Thayer
Journal:  J Gastrointest Surg       Date:  2009-09-17       Impact factor: 3.452

8.  Magnetic resonance pancreatography: comparison of two- and three-dimensional sequences for assessment of intraductal papillary mucinous neoplasm of the pancreas.

Authors:  Jin-Young Choi; Jeong Min Lee; Min Woo Lee; Soo Jin Kim; Sun Young Choi; Ji Yang Kim; Joon Koo Han; Byung Ihn Choi
Journal:  Eur Radiol       Date:  2009-04-18       Impact factor: 5.315

9.  PGE(2) in pancreatic cyst fluid helps differentiate IPMN from MCN and predict IPMN dysplasia.

Authors:  C Max Schmidt; Michele T Yip-Schneider; Matthew C Ralstin; Sabrina Wentz; John DeWitt; Stuart Sherman; Thomas J Howard; Lee McHenry; Sarah Dutkevitch; Michael Goggins; Attila Nakeeb; Keith D Lillemoe
Journal:  J Gastrointest Surg       Date:  2007-11-20       Impact factor: 3.452

10.  Pancreatic cystic lesions: clinical predictors of malignancy in patients undergoing surgery.

Authors:  E S Huang; B G Turner; C Fernandez-Del-Castillo; W R Brugge; C Hur
Journal:  Aliment Pharmacol Ther       Date:  2009-10-21       Impact factor: 8.171

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.